> ## Content Index > Fetch the complete content index at: https://newsletters.qs.com/llms.txt > Use this file to discover other available public pages before exploring further. # πŸ’Š Health Futures #36 - URL: https://newsletters.qs.com/health-futures-36/ - Published: 2024-09-23T11:30:52.000Z - Updated: 2024-09-23T11:30:51.000Z - Description: HolonIQ's Health Newsletter covers the latest developments in vaccinations, medical devices, and health software systems and highlights the week's top health deals. - Author: QS - Tags: Health Skills **Happy Monday πŸ‘‹** This week’s key health developments centered around vaccinations, medical devices, and practice management. In health vaccinations, after Morderna [received](https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/latest-pharmaceutical-manufacturing-news/moderna-overly-optimistic-respiratory-syncytial-virus-vaccination/?ref=newsletters.qs.com) approval for the RSV vaccine however Moderna is facing competition against GSK and Pfizer in the US market while Sanofi is meeting high demand by [shipping](https://www.pharmaceutical-technology.com/news/sanofi-shipping-beyfortus-us/?cf-view&ref=newsletters.qs.com) its RSV vaccine, Beyfortus for infants. In health devices, Presto Engineering [joined](https://www.med-technews.com/news/medical-device-news/presto-engineering-joins-medicalps-cluster-to-support-medical-device-innovations/?ref=newsletters.qs.com) the MEDICALPS cluster to partner with stakeholders in the medical device industry intending to seek better challenges from the manufacturers and provide customized ASIC solutions. In practice management, Ripple Therapeutics and AbbVie entered into a [collaboration](https://www.miragenews.com/ripple-abbvie-partner-for-next-gen-glaucoma-1318326/?ref=newsletters.qs.com) to develop a next-generation drug delivery implant for the treatment of glaucoma combining Ripple's drug delivery platform with AbbVie's expertise in eye care. In health funding, Zenas BioPharma raised [$225M](https://www.renaissancecapital.com/IPO-Center/News/106670/Immunology-biotech-Zenas-BioPharma-prices-upsized-IPO-at-$17-midpoint?ref=newsletters.qs.com) in a Series B funding round to advance the development of evaluated for obexelimab multiple indications including IgG4-RD, MS, and SLE. ## πŸ’‰ Vaccinations 🦠 **The World Health Organization** [**granted**](https://health.economictimes.indiatimes.com/news/industry/who-grants-first-mpox-vaccine-approval-to-ramp-up-response-to-disease-in-africa/113327418?ref=newsletters.qs.com) **its first authorization to vaccinate adults against m-pox.** The vaccine, manufactured by Bavarian Nordic, is effective in combating the disease in Africa, however, the supply is limited. πŸ’Š **Moderna faced challenges in RSV vaccines.** Moderna [struggling](https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/latest-pharmaceutical-manufacturing-news/moderna-overly-optimistic-respiratory-syncytial-virus-vaccination/?ref=newsletters.qs.com) to gain market share in RSV vaccines despite receiving FDA clearance for mResvia and the company is aiming to expand its market by targeting adults aged 18 to 59. πŸ‘Ά **Sanofi** [**shipping**](https://www.pharmaceutical-technology.com/news/sanofi-shipping-beyfortus-us/?cf-view&ref=newsletters.qs.com) **Beyfortus for RSV prevention in infants.** The drug is produced to protect infants from lower respiratory tract disease caused by RSV. Sanofi is increasing the production of the vaccines to demand for RSV. ## πŸ’» Medical Devices πŸ”§ **Presto Engineering**[ **joined**](https://www.med-technews.com/news/medical-device-news/presto-engineering-joins-medicalps-cluster-to-support-medical-device-innovations/?ref=newsletters.qs.com) **with the MEDICALPS cluster.** The partnership aimedtocollaborate with key players in the medical device industry. The company aims to gain a deeper understanding of the specific challenges and needs of medical device companies and deliver customized ASIC solutions. 🩹 **Alio sought** [**expanded**](https://www.medicaldevice-network.com/news/alio-starts-trial-to-expand-label-for-remote-monitoring-device/?cf-view&ref=newsletters.qs.com) **use for remote health monitoring devices.** Alio expanded the use of its SmartPatch technology to monitor health metrics in dialysis patients without vascular access sites. 🩸 **Argon Medical** [**launched**](https://www.prnewswire.com/news-releases/argon-medical-launches-cleaner-vac-thrombectomy-system-to-remove-blood-clot-in-the-peripheral-venous-vasculature-302248996.html?ref=newsletters.qs.com) **the Cleaner Vac Thrombectomy System.** The system is used for the removal of blood clots from the peripheral venous vasculature. The device is currently available in the US and offers a new treatment option for patients. ## 🌐 Health Software Systems πŸ”’ **RLDatix**[ **partners**](https://www.prnewswire.com/news-releases/rldatix-partners-with-patients-for-patient-safety-us-to-reduce-preventable-harm-302250236.html?ref=newsletters.qs.com) **with Patients for Patient Safety.** The partnership will focus on enhancing patient engagement, transparency, and accountability and to reduce preventable harm in healthcare. πŸ“Ά **Kajeet**[ **partners**](https://www.prnewswire.com/news-releases/kajeet-and-avery-telehealth-announce-strategic-partnership-to-accelerate-telehealth-and-rpm-solutions-delivery-302250104.html?ref=newsletters.qs.com) **with Avery Telehealth.** The partnership aims to accelerate the deployment of digital health solutions hence enable This partnership will enable Avery Telehealth to expand its reach and offer high-quality telehealth services to a wider range of patients. 🧬 **Ripple Therapeutics and AbbVie entered into a collaboration.** The [partnership ](https://www.miragenews.com/ripple-abbvie-partner-for-next-gen-glaucoma-1318326/?ref=newsletters.qs.com)aimed to develop RTC-620, a next-generation drug delivery implant for the treatment of glaucoma. ## **πŸ’°** Deals of the Week πŸ’Š **Zenas BioPharma** raised [$225M](https://www.renaissancecapital.com/IPO-Center/News/106670/Immunology-biotech-Zenas-BioPharma-prices-upsized-IPO-at-$17-midpoint?ref=newsletters.qs.com) in a Series B funding round. The company plans to use the funds to advance the development of its lead candidate, obexelimab. βš™οΈ **SerΓ‘n Bioscience** raised [$200M](https://www.fiercepharma.com/pharma/cdmo-seran-snags-200m-bain-investment-build-its-first-commercial-facility?ref=newsletters.qs.com) and plans to build a new commercial production plant. The company aims to offer a range of services, including particle engineering and finished dose forms. πŸ₯ **Max Healthcare** entered a strategic collaboration to acquire a controlling stake in **Jaypee Healthcare** for \~[$198M](https://finance.yahoo.com/news/india-max-healthcare-acquire-stake-083528331.html?ref=newsletters.qs.com). The acquisition includes Jaypee's 500-bed hospital in Noida and two other hospitals. πŸ§ͺ **Cinven**, a private equity firm, is selling a minority stake in **Synlab**, a European medical diagnostic services and specialty testing provider for [$156M.](https://www.investorsinhealthcare.com/articles/category/news/germany-cinven-to-sell-minority-stake-in-synlab-to-strategic-investor-labcorp/?ref=newsletters.qs.com) πŸ”¬ **F2G**, a clinical-stage biopharmaceutical company, raised [$100M](https://www.finsmes.com/2024/09/f2g-raises-100m-in-financing.html?ref=newsletters.qs.com) in funding. The company plans to use the funds to complete the late-stage development of olorofim, seek regulatory approval, and prepare for commercialization in the US. --- **Thank you for reading. Have a great week ahead!** Have some feedback or suggestions? Let us know at hello@holoniq.com [ ](https://newsletters.qs.com/psychedelic-mental-health-treatments-south-asia-health-tech-100-2/)